Clinical trials
11 active studies led by Inmunotek S.L., of 26 in all
Source: ClinicalTrials.gov, Studies with Inmunotek S.L. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 3Markets in public records
- 0Regions & countries
- 11Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Inmunotek S.L. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on Inmunotek S.L.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
See them on ClinicalTrials.gov (opens in a new tab)
Trials over time
Studies Inmunotek S.L. leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Inmunotek S.L. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show Inmunotek S.L.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Inmunotek S.L. is in.
From our blog
Stories on the topics Inmunotek S.L. works in.
Bone and Joint Health: Supplements for an Ageing Population
1.71 billion people live with musculoskeletal conditions, including 528 million with osteoarthritis. Evidence…
Read
Eye Health Supplements: Screens, Ageing and Vision
2.2 billion people have a vision impairment. One supplement formula has strong trial evidence, but only for a…
Read
Collagen Supplements: Skin, Joints and Real Evidence
Collagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
Read